Listed by the USPTO as STEELE, AMBER D
Tech Center 1600 • Art Units: 1627 1639 1645 1654 1658 1676
This examiner grants 59% of resolved cases
STEELE, AMBER D examines applications in technology center 1600 and art unit 1627. Her profile contains 831 resolved cases, an allowance rate of 58.8%, and an interview lift of 9.6%. The median time to allowance is 1254 days. The large resolved-case record supports using these figures as a meaningful historical reference when evaluating prosecution options in the assigned art unit.
The principal listed companies are Mayo Foundation for Medical Education and Research, Arizona Board of Regents on Behalf of the University of Arizona, and Lateral Ip Pty Ltd. The recurring firms are FOLEY & LARDNER LLP, Apex Attorneys at Law, LLP, and Bay State IP, LLC. Counsel can combine the stakeholder information with the allowance and timing figures when planning interviews, amendments, and portfolio-level expectations.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17778306 | POLYPEPTIDE INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY AND USES THEREOF | Non-Final OA | The Regents of the University of Michigan |
| 18746401 | ANTIMICROBIAL PEPTIDES AND METHODS OF USING SAME | Non-Final OA | Zoetis Services LLC |
| 18404131 | MANP Analogues | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 17768537 | Bi-Peptide with Affinity to Extracellular Matrix Proteins or Cells and to Growth Factors for Tissue Healing and Regeneration | Final Rejection | Mayo Foundation for Medical Education and Research |
| 18564739 | Substrate-specific adhesive peptides | Final Rejection | HENKEL AG & CO. KGAA |
| 18700680 | A RECOMBINANT REFLECTIN NANOPARTICLE | Non-Final OA | NANYANG TECHNOLOGICAL UNIVERSITY |
| 18580971 | COMPOSITION FOR PREVENTING OR TREATING LIVER DISEASES, COMPRISING STC-1 OR DERIVATIVE THEREOF | Final Rejection | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18265523 | SCG2 NEUROPEPTIDES AND USES THEREOF | Final Rejection | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 17760668 | Conformationally-Constrained Alpha-RGIA Analogues | Final Rejection | University of Utah Research Foundation |
| 16632226 | COMPOSITIONS AND METHODS COMPRISING SELF-ASSEMBLING PEPTIDE-POLYMER NANOFIBERS FOR SUBLINGUAL IMMUNIZATION | Non-Final OA | Duke University |
| 18533699 | COMPOSITION AND METHOD FOR PROLONG SURVIVAL OF TRANSPLANT AND RECIPIENT | Non-Final OA | SEOUL NATIONAL UNIVERSITY HOSPITAL |
| 18797990 | METHODS AND COMPOSITIONS FOR TREATING CANCERS AND OTHER PROLIFERATIVE DISORDERS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 18037098 | VIBRIO TOXIN BINDING PROTEINS IN SHRIMP AND USES THEREOF | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 18290872 | ANTI-FUNGAL GRIFFITHSIN COMPOSITIONS AND METHODS OF USE | Non-Final OA | University of Louisville Research Foundation, Inc. |
| 17396304 | Growth Hormone-Releasing Hormone Antagonists and Uses Thereof | Non-Final OA | University of Miami |
| 18245226 | A SYSTEM TO IMPROVE HAEMOSTATIC CONTROL | Non-Final OA | Tissue-Link ApS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy58.8% of resolved applications examined by Amber D Steele were allowed (831 resolved cases), compared with 35.4% across Art Unit 1627 over the last five years.
This examiner's interview lift is +9.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Amber D Steele took 1,254 days on average from filing to allowance.
Amber D Steele examines applications in Art Unit 1627 in Tech Center 1600 (Biotechnology & Pharmaceuticals).